Susan Ellenberg, PhD, comments on the state of COVID-19 vaccine development: She hopes people are reassured by the AstraZeneca trial's pause for safety and says it's unlikely that we’ll have a vaccine this fall.
New COVID-19 infections were about 30 percent lower in counties where the highest number of people stopped going in to their offices for work, found research led by Joshua Baker, MD, MSCE.
When we’re offered a COVID-19 vaccine, we should ask: Does it protect people, without causing major toxicities or health problems? If so—and after the FDA and its expert committees review— “I will certainly be in line to get one," Susan Ellenberg, PhD, commented on the radio show Ask an Expert.
For tuberculosis patients who are also HIV-positive, mortality risk is up to four times higher. Gregory Bisson, MD, MSCE, comments on how we can dramatically improve their chances.
For a useful COVID-19 analogy, look to the time before antilock brakes, says Michael Levy, PhD. “You had to slam on the brakes, ease up a little and apply the brakes again—and eventually the car would stop.”
Some of COVID-19's scientific challenges resemble those faced in the past—with HIV, SARS, H1N1 and Ebola—while others are new. Susan Ellenberg, PhD, unpacks what we need to know about clinical trials during the current pandemic. Read the perspective piece in Clinical Trials.
Seeing groups hanging out together at concerts, bars and parties with few masks in sight, “It’s not surprising that people are spreading the virus,” Ebbing Lautenbach, MD, MPH, MSCE, told Philadelphia’s NBC10.
Jordana Cohen, MD, MSCE, and co-investigator Julio Chirinos, MD, launched an international, multisite study to find out more about how ACE inhibitors and ARBS affect COVID-19. They are cautious about the drugs’ effects until they finish their research.
